KM Pharmaceutical Largest Shareholder Kang Il-mo Increases Stake by 0.26% via Open Market Purchase, Now Holds 39.60%
Largest shareholder Kang Il-mo acquired an additional 14,421 shares of KM Pharmaceutical through open market purchases on June 26 and 29, 2026, raising his holding from 39.34% to 39.60%.
The acquisition funds of approximately KRW 25 million were sourced from personal earned income with no borrowing involved.
Out of 2,209,061 shares held by Kang and related parties, 1,197,489 shares or about 21.47% remain pledged to IBK Investment & Securities and Industrial Bank of Korea with loan extensions in place.
[AI Summary]The largest shareholder's small open market purchase signals commitment to control, but the high proportion of pledged shares poses liquidity risk. There is no new capital raising or business change, making this event neutral for investment sentiment.